170 related articles for article (PubMed ID: 37799595)
21. Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.
Wiedemeyer WR; Beach JA; Karlan BY
Front Oncol; 2014; 4():34. PubMed ID: 24624361
[TBL] [Abstract][Full Text] [Related]
22. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.
Choi YE; Battelli C; Watson J; Liu J; Curtis J; Morse AN; Matulonis UA; Chowdhury D; Konstantinopoulos PA
Oncotarget; 2014 May; 5(9):2678-87. PubMed ID: 24798692
[TBL] [Abstract][Full Text] [Related]
23. BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
Royfman R; Whiteley E; Noe O; Morand S; Creeden J; Stanbery L; Hamouda D; Nemunaitis J
Future Oncol; 2021 Jul; 17(21):2817-2830. PubMed ID: 34058833
[TBL] [Abstract][Full Text] [Related]
24. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
25. CXCL10 and CCL5 as feasible biomarkers for immunotherapy of homologous recombination deficient ovarian cancer.
Han Y; Guo Z; Jiang L; Li X; Chen J; Ouyang L; Li Y; Wang X
Am J Cancer Res; 2023; 13(5):1904-1922. PubMed ID: 37293164
[TBL] [Abstract][Full Text] [Related]
26. Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients.
Zhou Z; Ding Z; Yuan J; Shen S; Jian H; Tan Q; Yang Y; Chen Z; Luo Q; Cheng X; Yu Y; Niu X; Qian L; Chen X; Gu L; Liu R; Ma S; Huang J; Chen T; Li Z; Ji W; Song L; Shen L; Jiang L; Yu Z; Zhang C; Tai Z; Wang C; Chen R; Carbone DP; Xia X; Lu S
J Hematol Oncol; 2022 May; 15(1):62. PubMed ID: 35585646
[TBL] [Abstract][Full Text] [Related]
27. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
[TBL] [Abstract][Full Text] [Related]
28. Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Shi Z; Zhao Q; Lv B; Qu X; Han X; Wang H; Qiu J; Hua K
Clin Transl Med; 2021 May; 11(5):e399. PubMed ID: 34047476
[TBL] [Abstract][Full Text] [Related]
29. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D
Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276
[TBL] [Abstract][Full Text] [Related]
30.
Mirza MR; Lindahl G; Mahner S; Redondo A; Fabbro M; Rimel BJ; Herrstedt J; Oza AM; Canzler U; Berek JS; González-Martín A; Follana P; Lord R; Azodi M; Estenson K; Wang Z; Li Y; Gupta D; Matulonis U; Feng B
Cancer Res Commun; 2022 Nov; 2(11):1436-1444. PubMed ID: 36970052
[TBL] [Abstract][Full Text] [Related]
31. EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.
Karakashev S; Fukumoto T; Zhao B; Lin J; Wu S; Fatkhutdinov N; Park PH; Semenova G; Jean S; Cadungog MG; Borowsky ME; Kossenkov AV; Liu Q; Zhang R
Cancer Cell; 2020 Feb; 37(2):157-167.e6. PubMed ID: 32004442
[TBL] [Abstract][Full Text] [Related]
32. Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Lee A
Target Oncol; 2021 Nov; 16(6):839-845. PubMed ID: 34635996
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
Yanaihara N; Yoshino Y; Noguchi D; Tabata J; Takenaka M; Iida Y; Saito M; Yanagida S; Iwamoto M; Kiyokawa T; Chiba N; Okamoto A
Gynecol Oncol; 2023 Jan; 168():83-91. PubMed ID: 36403366
[TBL] [Abstract][Full Text] [Related]
34. Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
Gynecol Oncol; 2023 Feb; 169():173. PubMed ID: 36456375
[No Abstract] [Full Text] [Related]
35. Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer.
Yang D; Huang FX; Wei W; Li QQ; Wu JW; Huang Y; Li ZL; Zhang HL; Li X; Yuan QE; Chen QS; Feng GK; Rong D; Li JD; Zhu XF
Int J Biol Sci; 2023; 19(6):1846-1860. PubMed ID: 37063431
[TBL] [Abstract][Full Text] [Related]
36. Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
Xie T; Dickson KA; Yee C; Ma Y; Ford CE; Bowden NA; Marsh DJ
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230543
[TBL] [Abstract][Full Text] [Related]
37. Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer.
Zhou C; Wei Z; Zhang L; Yang Z; Liu Q
Front Oncol; 2020; 10():593989. PubMed ID: 33363023
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
39. Deciphering the expression patterns of homologous recombination-related lncRNAs identifies new molecular subtypes and emerging therapeutic opportunities in epithelial ovarian cancer.
Hua T; Zhang XC; Wang W; Tian YJ; Chen SB
Front Genet; 2022; 13():901424. PubMed ID: 36246624
[TBL] [Abstract][Full Text] [Related]
40. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
da Cunha Colombo Bonadio RR; Fogace RN; Miranda VC; Diz MDPE
Clinics (Sao Paulo); 2018 Aug; 73(suppl 1):e450s. PubMed ID: 30133561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
